Showing results (91-100 of 121) with videos related to
Sort By:
Pageof 13
The Journal of Pathology|July 26, 2020
miRNA profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axisMoritz A Loeffler, Jun Hu, Martina Kirchner, et al.Annals of Surgery|July 11, 2020
Actual Five-year Survival After Upfront Resection for Pancreatic Ductal Adenocarcinoma: Who Beats the Odds?Oliver Strobel, Philipp Lorenz, Ulf Hinz, et al.BMC Cancer|October 7, 2021
Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinomaMarcell Tóth, Lilija Wehling, Lena Thiess, et al.Clinical and Translational Science|November 3, 2023
Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacyNicolas Hohmann, Martin Ronald Sprick, Moritz Pohl, et al.Journal of Cachexia, Sarcopenia and Muscle|August 24, 2021
Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapyPauline Morigny, Doris Kaltenecker, Julia Zuber, et al.JHEP Reports : Innovation in Hepatology|May 13, 2024
Carbon ion radiotherapy of hepatocellular carcinoma provides excellent local control: The prospective phase I PROMETHEUS trialPhilipp Hoegen-Saßmannshausen, Patrick Naumann, Paula Hoffmeister-Wittmann, et al.The New England Journal of Medicine|June 1, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerEileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.Nature Cancer|September 7, 2023
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDACXu Zhou, Jingyu An, Roma Kurilov, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study GroupRalf-Dieter Hofheinz, Kirsten Merx, Georg M Haag, et al.Journal of the National Cancer Institute|December 1, 2025
NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancerDylan Williams, Chandni Patel, Kate Murray, et al.Pageof 13